CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
July 2016—Protagen gained CE marking for its Multilisa BICD2 test. BICD2 is a proprietary biomarker discovered by Protagen using the SeroTag technology platform. The test is intended for the semiquantitative determination of autoantibodies to BICD2, an evolutionarily conserved motor adaptor protein involved in the dynein-mediated transport process.
Protagen, +49 231 9742 6300